Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Improving vaccines against tuberculosis.

Warwick J Britton1, Umaimainthan Palendira

  • 1Centenary Institute of Cancer Medicine and Cell Biology, Newtown, New South Wales, Australia. wbritton@medicine.usyd.edu.au

Immunology and Cell Biology
|January 22, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhanced measures of neoantigenicity capture unique tumor-immune interactions across primary melanoma subtypes.

Genome medicine·2026
Same author

Targeted delivery of the BCG vaccine to dendritic cells improves protective efficacy against Mycobacterium tuberculosis.

Vaccine·2026
Same author

CSF1R-dependent CD169-positive macrophages locally constrain melanoma growth in the skin.

The Journal of experimental medicine·2026
Same author

ClpC1-targeting peptide natural products differentially dysregulate the proteome of Mycobacterium tuberculosis.

Nature communications·2026
Same author

Efficacy of Inhalable Endolysin Cpl-1 Formulations in Combination with Gentamicin or Endolysin Pal in a Murine Lung Infection Model.

Pharmaceutical research·2026
Same author

ClpC1 Modulating Ohmyungsamycin A and Ecumicin Natural Product Analogues are Potent Antimycobacterials.

ACS infectious diseases·2025
Same journal

Ancestry Matters in Decoding Immunity.

Immunology and cell biology·2026
Same journal

Improving COVID-19 Vaccine Uptake Among Ethnic Minority Communities in Wales: A Community-Based Approach.

Immunology and cell biology·2026
Same journal

4-1BB Expression and Signaling Regulates MAIT Cell Activation and Effector Functions.

Immunology and cell biology·2026
Same journal

Highlights of 2025: Advances in the T-Cell Regulation of Germinal Center Response.

Immunology and cell biology·2026
Same journal

The Role of the IL-33/ST2 Axis in Nervous System Development and Diseases.

Immunology and cell biology·2026
Same journal

Bridging Science and Society: Public Engagement as a Catalyst for Infectious Disease Control and Prevention.

Immunology and cell biology·2026
See all related articles

Developing new tuberculosis vaccines is crucial as BCG has limitations. Novel approaches combining genetic manipulation and subunit vaccines show promise for enhanced protection against tuberculosis.

Area of Science:

  • Infectious Diseases
  • Vaccinology
  • Immunology

Background:

  • Tuberculosis (TB) remains a significant global health challenge, causing mortality and socioeconomic impact.
  • The current BCG vaccine has limitations, including waning immunity and reduced efficacy in certain forms of TB.
  • Advances in understanding Mycobacterium tuberculosis and host immunity offer opportunities for improved vaccines.

Purpose of the Study:

  • To review current strategies for developing a more effective tuberculosis vaccine than BCG.
  • To discuss novel live and subunit vaccine approaches.
  • To evaluate the potential of cytokine adjuvants and antigen-presenting cell targeting strategies.

Main Methods:

  • Review of current research on Mycobacterium tuberculosis genetics and host immunity.

Related Experiment Videos

  • Analysis of live vaccine strategies, including attenuated strains and genetically modified BCG.
  • Evaluation of subunit vaccine approaches, including protein and DNA vaccines, with cytokine adjuvants.

    • Main Results:

    • Both live and subunit vaccines have shown partial protection in experimental models, often comparable to BCG.
    • Co-administration of interleukin-12 and Antigen 85B DNA vaccine demonstrated BCG-level protection.
    • Priming with DNA-85B and boosting with BCG surpassed BCG alone in efficacy.

    Conclusions:

    • New tuberculosis vaccine strategies can achieve protection levels superior to BCG.
    • Genetic manipulation of BCG and subunit vaccines, particularly when combined, hold significant potential for human TB vaccines.